Savara Inc.

SVRA

NASDAQ

Healthcare

Biotechnology

Langhorne, TX, US59 employeessavarapharma.com

$5.57

-0.01(-0.27%)

Mkt Cap $1.1B

$1.94

$6.94

52-Week Range

At a Glance

AI-generated

Savara Inc.

8-K

Savara Inc. entered into an Agreement of Lease with ML7 Yardley Partners, LP on March 10, 2026. The lease is disclosed under Item 1.01 as a material definitive agreement, with Exhibit 10.1 attached.

$1.1B

Market Cap

—

Revenue

-$109M

Net Income

Employees59

Fundamentals

How The Business Makes Money

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Industry Biotechnology

Activity

What Changed Recently

Material Agreement

Mar 12, 2026

. Entry into a Material Definitive Agreement. On March 10, 2026, Savara Inc. (the “Company”) entered into an Agreement of Lease (the “Lease”) with ML7 Yardley P

Material Agreement

Jan 26, 2026

. Entry into a Material Definitive Agreement. On January 26, 2026, Savara Inc. (the “Company”) entered into a First Amendment (the “First Amendment”) to the Loa

Regulation FD

Jan 8, 2026

in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that S

Peer Companies

Company	Price	Change	Market Cap	P/E
TNGXTango Therapeutics, Inc.	$21.66	+2.07%	$2.5B	-21.7
TYRATyra Biosciences, Inc.	$39.38	+2.89%	$2.1B	-18.1
NBTXNanobiotix S.A.	$31.09	-8.76%	$1.5B	-23.8
BCAXBicara Therapeutics Inc. ...	$21.48	+4.78%	$1.2B	-8.3
EYPTEyePoint Pharmaceuticals,...	$13.41	+3.00%	$1.1B	-4.6
GERNGeron Corporation	$1.66	-0.30%	$1.1B	-12.0
GHRSGH Research PLC	$14.47	-1.66%	$898M	-17.0
KURAKura Oncology, Inc.	$8.62	+3.36%	$761M	-2.6

Analyst View

Company Profile

CIK0001160308

ISINUS8051111016

CUSIP805111101

Phone512 614 1848

AddressBuilding III, Langhorne, TX, 78746, US

SEC EDGAR